DF2001 / Dragonfly Therap - LARVOL DELTA

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16/NKG2D Immune Modulating TriNKET® BMS-986357 (CC-96191) (ASH 2023) - P1 | "CD33 is widely expressed by myeloid cells and is a validated drug target in acute myeloid leukemia (AML), as shown by the benefit of some patients from the CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO)...In summary, our findings demonstrate that BMS-986357 TriNKET® has potent CD33-dependent cytolytic activity in vitro against human AML cells, supporting the drug's exploration in early phase clinical trials. One such trial (NCT04789655) has opened accrual for adults with relapsed/refractory AML."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33 • CSF2 • FCGR3A • IFNG • IL6 • NKG2D

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=45 | Terminated | Sponsor: Celgene | N=80 ➔ 45 | Active, not recruiting ➔ Terminated; Business objectives have changed

Enrollment change • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=80 | Active, not recruiting | Sponsor: Celgene | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191. (PubMed, Cancers (Basel)) - P1 | "Finally, in patient marrow specimens, CC-96191 eliminated AML cells but not normal monocytes, suggesting selectivity of TriNKET-induced cytotoxicity toward neoplastic cells. Together, these findings support the clinical exploration of CC-96191 as in NCT04789655."

IO biomarker • Journal • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • BCL2 • CD33 • FCGR3A • NKG2D

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1; N=70; Recruiting; Sponsor: Celgene; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb and Receipt of Milestone Payments Following First Patient Dosing of Two TriNKET Immunotherapies (PRNewswire) - "Dragonfly Therapeutics, Inc...announced that Bristol Myers Squibb has licensed a fifth TriNKET™ Immunotherapy drug candidate, bringing the total drug candidates licensed by Bristol Myers Squibb to six including Dragonfly's novel IL-12 cytokine DF6002/BMS-986415. Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets....Dragonfly also announced that the first patients have been dosed in Phase 1 clinical trials of both the CC-96191 and CC-92328 investigational immunotherapies, which are licensed to Bristol Myers Squibb."

Licensing / partnership • Trial status • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1; N=70; Not yet recruiting; Sponsor: Celgene

Clinical • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology